GlassScriptPhysician profile
Gary M Winfrey
NPI 1396034526
$1,419.08
in general payments reported to CMS, 2019-2025
26 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $281 · 2023: $473 · 2024: $337 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $224.07 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $172.64 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $137.09 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $116.14 | 2023-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $100.77 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $74.82 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $71.90 | 2022-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Antares Pharma, INC. | $57.83 | 2022-2024 | Xyosted |
| Pfizer INC. | $56.33 | 2023-2025 | |
| Abbvie INC. | $40.90 | 2023-2024 | Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.74 | 2023-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $38.55 | 2024 | Veozah |
| Abbott Laboratories | $31.87 | 2022-2023 | Freestyle Libre 3 |
| Tolmar, INC. | $30.20 | 2025 | Jatenzo |
| Eisai INC. | $25.91 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $22.66 | 2023 | Aptima, Thinprep 2000 Processor |
| Axsome Therapeutics, INC. | $21.81 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.15 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.98 | 2022 | |
| Indivior INC. | $20.06 | 2023 | Sublocade |
| Phadia US INC. | $18.95 | 2023 | Immunocap |
| Idorsia Pharmaceuticals US INC | $17.51 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $16.65 | 2023 | Nexletol |
| Sanofi Pasteur INC. | $14.11 | 2023 | |
| Inspire Medical Systems, INC. | $13.76 | 2025 | Inspire |
| Shield Therapeutics INC | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Winfrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.